Skip to content

The Impact of Low-Dose Esketamine on Postoperative Depression and Cognitive Function in Elderly Patients Undergoing Laparoscopic Gastrointestinal Tumor Surgery

The Impact of Low-Dose Esketamine on Postoperative Depression and Cognitive Function in Elderly Patients Undergoing Laparoscopic Gastrointestinal Tumor Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117996
Enrollment
Unknown
Registered
2026-01-30
Start date
2026-02-04
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative depression and cognitive dysfunction in elderly patients

Interventions

Es-ketamine group:During anesthesia induction, in addition to the routine use of anesthetic drugs, the observation group (Group E) was administered esketamine at a dose of 0.25 mg/kg
During the maintenance phase of anesthesia, esketamine is continuously administered via intravenous infusion at a rate of 0.125 mg/(kg·h), and the infusion is discontinued 20 minutes before the end of
Control group:During both anesthesia induction and maintenance, an equal volume of 0.9% normal saline was administered.

Sponsors

Yijishan Hospital, the First Affiliated Hospital of Wannan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Scheduled for laparoscopic resection of gastrointestinal tumors; 2.Age >=65 years; 3.ASA classification I-III; 4.No cognitive impairment or mental disorders before the operation.

Exclusion criteria

Exclusion criteria: 1.Refusal to participate in the study; 2.Individuals with communication barriers; 3.Those allergic to esketamine or with contraindications for its use; 4.Patients with severe liver, kidney, lung, or cardiovascular diseases before surgery; 5.Severe acute infections.

Design outcomes

Primary

MeasureTime frame
Scores on the Hospital Anxiety and Depression Scale were obtained through follow - up assessments before surgery, 3 days after surgery, 1 week after surgery, and 1 month after surgery.;Pre - operatively, as well as at 3 days, 1 week, and 1 month post - operatively, the Mini - Mental State Examination (MMSE) was employed to assess the patients' cognitive function.;Cytokine:tumor necrosis factor a (TNFa), interleukin - 6 (IL - 6), and the related factor S100 calcium - binding protein ß (S100ß protein) were measured using the enzyme - linked immunosorbent assay (ELISA).;

Secondary

MeasureTime frame
Resting Visual Analog Scale (VAS) scores at 2, 6, 12, 24, and 48 hours post - operation;VAS scores during activities at 12 h, 24 h, and 48 h after surgery;The intraoperative dosages of propofol and sufentanil;Whether additional analgesic medications were administered within 48 hours after the surgery;At various time points, including the baseline (T0), intubation (T1), skin incision (T2), after pneumoperitoneum (T3), and 5 minutes after extubation (T4), the levels of mean arterial pressure (MAP) and heart rate (HR) were measured using a multi-parameter physiological monitor.;Instances of adverse reactions such as dizziness, nausea and vomiting, polyglot agitation, and nightmares;

Countries

China

Contacts

Public ContactWei Chen;Yan Lu

Yijishan Hospital, the First Affiliated Hospital of Wannan Medical College

yjsdrluyan1987@163.com+86 187 1530 1107

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026